Novan is a medical dermatology company focused on developing and commercializing therapeutic products for skin diseases. Co. is developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum. Co.'s commercial portfolio includes six prescription drugs. These prescription dermatology therapies are targeted to patients with plaque psoriasis, rosacea, and acne. The product portfolio includes Wynzora Cream (calcipotriene and betamethasone dipropionate cream), Rhofade (oxymetazoline hydrochloride cream, 1%), and Minolira (biphasic minocycline hydrochloride immediate release/extended release tablets). The NOVN average annual return since 2016 is shown above.
The Average Annual Return on the NOVN average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NOVN average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NOVN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|